Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Research Project Brain Tumor Program Point of View How to Engage Your Employees During a Pandemic Our Impact, Patient Story A Legacy of Service and a New Day for Pancreatic Cancer Cancer Research Heroes, Our Impact The Power and Promise of High-Risk Science Announcement, Our Impact, Press Release, Research Update Neoantigen Alliance IDs Parameters for Cancer Vaccines Announcement, Press Release PICI Appoints John Connolly as Chief Scientific Officer
Announcement, Our Impact, Press Release, Research Update Neoantigen Alliance IDs Parameters for Cancer Vaccines